首页 > 市场调查报告书 > 医疗设备

体外诊断癌症癌症诊断

市场调查报告书

商品编码

1634194

全球下一代癌症诊断设备市场 - 2025 - 2033

Global Next Generation Cancer Diagnostic Devices Market - 2025 - 2033

出版日期: 2025年01月13日 | 出版商:

DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024年，全球下一代癌症诊断设备市场规模达到181.2亿美元，预计2033年将达到611.4亿美元，2025-2033年预测期间复合年增长率为15.2%。

下一代癌症诊断设备 (NGCD) 是用于在分子层面上识别和表征癌症的先进技术和程序。这些设备使用复杂的方法，特别是次世代定序 (NGS)，提供对肿瘤遗传学的详细了解，从而实现早期识别、客製化治疗方案和更好的患者治疗效果。下一代癌症诊断设备是一系列仪器和技术，使用高通量定序技术来评估癌细胞的遗传物质。 NGS 能够同时对数百万个 DNA 片段进行定序，从而检测与多种癌症相关的基因突变、变化和生物标记。与传统方法相比，这种能力显着增强了诊断过程，传统方法通常专注于单一或有限的遗传目标。

对下一代癌症诊断设备的需求不断增长是预测期内推动市场的驱动因素。癌症病例数量的增加增加了对癌症检测和癌症肿瘤全面基因组分析的需求，以分析癌症的状态并相应地设计治疗方法。例如，根据 nih.gov 2023 年 1 月发表的一篇文章，预计 2023 年美国将出现 1,958,310 例新癌症病例和 609,820 例癌症死亡。在经历了二十年的下降之后，从 2014 年到 2019 年，前列腺癌的发生率每年增加 3%，意味着新增病例增加了 99,000 例。

市场动态：

驱动程式和限制

对下一代癌症诊断设备的需求不断增长

对下一代癌症诊断设备的需求不断增长预计将成为全球下一代癌症诊断设备市场成长的重要因素。全球下一代癌症诊断设备市场预计将大幅扩张，这主要是由于癌症盛行率不断上升、技术进步、最近的产品发布和批准、战略合作伙伴关係以及人们意识的提高。

癌症病例数量的增加增加了对癌症检测和癌症肿瘤全面基因组分析的需求，以分析癌症的状态并相应地设计治疗方案。因此，癌症病例数量的增加增加了对下一代癌症诊断设备的需求。此外，根据世界癌症研究基金会的数据，包括非黑色素瘤皮肤癌(NMSC) 在内，2022 年全球癌症病例数为19,976,499 例。 9,566,825 例为男性为 9,175,141，女性为 9,175,141。此外，根据 IARC 的数据，2022 年将有近 2,000 万新发癌症病例（包括非黑色素瘤皮肤癌 [NMSC]），同时有 970 万人死于癌症（包括 NMSC）。据估计，大约五分之一的男性或女性一生中会罹患癌症，而大约九分之一的男性和十二分之一的女性会死于癌症。肺癌是 2022 年最常被诊断出的癌症，导致近 250 万新病例，即全球八分之一的癌症之一（占全球所有癌症的 12.4%）。

此外，技术的进步显着增强了 NGCD 的功能，使其在医疗应用中受益。自动化系统和快速现场护理测试的整合简化了诊断实验室的操作，从而缩短了周转时间并提高了效率。例如，2024 年8 月，实验室自动化和创新领域的全球领导者Beckman Coulter Life Sciences 与DNA 定序和阵列技术领域的领导者Illumina 合作，为肿瘤学研究提供了一种有前途的新方法，该方法可以更快地提供结果更少的接触点。 Beckman Coulter Life Sciences 的 Biomek NGeniuS 系统的 Illumina TruSight Oncology 500 DNA/RNA 测试是一种创新的自动化方法，用于对肿瘤样本进行全面的基因组分析。

先进诊断技术的高成本

先进诊断技术的高成本等因素预计将阻碍全球下一代癌症诊断设备市场。这些支出可能会严重阻碍广泛采用，特别是在资源有限的医疗保健系统中。例如，下一代定序 (NGS) 测试的成本可能相差很大，每次测试从 1,000 美元到 10,000 美元不等，具体取决于所需分析的复杂性和范围。这种财务负担可能会阻碍医疗保健提供者投资这些现代诊断设备，特别是在医疗保健资金有限的低收入和中等收入国家。此外，安装 NGCD 技术所需的初始投资也很大。设施必须获得先进的设备，例如 NGS 平台，其成本从 150,000 美元到 500,000 美元不等。这些高昂的成本限制了客户购买设备并阻碍了市场。

有关此报告的更多详细资讯 - 索取样品

Next Generation Cancer Diagnostic Devices (NGCD) are advanced technologies and procedures used to identify and characterize cancer at the molecular level. These devices use sophisticated methods, particularly Next-Generation Sequencing (NGS), to provide detailed insights into tumor genetics, allowing for earlier identification, customized treatment regimens, and better patient outcomes. Next Generation Cancer Diagnostic Devices are a collection of instruments and technology that use high-throughput sequencing techniques to evaluate genetic material from cancer cells. NGS enables the simultaneous sequencing of millions of DNA fragments, allowing for the detection of genetic mutations, changes, and biomarkers linked to many types of cancer. This capability significantly enhances the diagnostic process compared to traditional methods, which often focus on single or limited genetic targets.

The increasing demand for next-generation cancer diagnostic devices is the driving factor that drives the market over the forecast period. The increasing number of cancer cases increases the demand for cancer testing and the comprehensive genomic profiling of the cancer tumor to analyze the state of the cancer and design the treatment accordingly. For instance, according to an article published by nih.gov in January 2023, in 2023, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the United States. Cancer incidence increased for prostate cancer by 3% annually from 2014 through 2019 after two decades of decline, translating to an additional 99,000 new cases.

Market Dynamics: Drivers & Restraints

Increasing demand for next-generation cancer diagnostic devices

The increasing demand for next-generation cancer diagnostic devices is expected to be a significant factor in the growth of the global next-generation cancer diagnostic devices market. The global next-generation cancer diagnostic devices market is poised for significant expansion, owing mostly to the rising prevalence of cancer, technological advancements, recent product launches and approvals, strategic partnerships, and increasing awareness among people.

The increasing number of cancer cases increases the demand for cancer testing and the comprehensive genomic profiling of the cancer tumor to analyze the state of the cancer and design the treatment accordingly. So, the increasing number of cancer cases increases the demand for next-generation cancer diagnostic devices. Moreover, according to the World Cancer Research Fund, including non-melanoma skin cancer (NMSC) there were 19,976,499 cancer cases in 2022. When NMSC was excluded, this number dropped to 18,741,966 cancer cases around the world in 2022. Of these, 9,566,825 were in men and 9,175,141 in women. Moreover, according to IARC, There were close to 20 million new cases of cancer in the year 2022 (including nonmelanoma skin cancers [NMSCs]) alongside 9.7 million deaths from cancer (including NMSC). The estimates suggest that approximately one in five men or women develop cancer in a lifetime, whereas around one in nine men and one in 12 women die from it. Lung cancer was the most frequently diagnosed cancer in 2022, responsible for almost 2.5 million new cases, or one in eight cancers worldwide (12.4% of all cancers globally).

Furthermore, advancements in technology have significantly enhanced the capabilities of NGCDs, making them beneficial in medical applications. The integration of automated systems and rapid point-of-care testing has simplified operations in diagnostic labs, resulting in faster turnaround times and increased efficiency. For instance, in August 2024, Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, collaborated with Illumina, a leader in DNA sequencing and array-based technologies, to offer a promising new approach to oncology research that delivers faster results with fewer touch points. Beckman Coulter Life Sciences' Illumina TruSight Oncology 500 DNA/RNA test for the Biomek NGeniuS System is an innovative automated approach for comprehensive genomic profiling of tumor samples.

High costs of advanced diagnostics technologies

Factors such as high costs of advanced diagnostics technologies are expected to hamper the global next-generation cancer diagnostic devices market. These expenditures can be a significant impediment to widespread adoption, especially in healthcare systems with limited resources. For example, the cost of next-generation sequencing (NGS) tests can vary greatly, ranging from $1,000 to $10,000 per test, depending on the complexity and scope of the analysis needed. This financial burden may discourage healthcare providers from investing in these modern diagnostic equipment, particularly in low- and middle-income countries where healthcare funding is limited. Furthermore, the initial investment needed to install NGCD technologies is significant. Facilities must obtain advanced equipment, such as NGS platforms, which can cost anywhere from $150,000 to $500,000. These high costs restrict the customers from buying the devices and hamper the market.

For more details on this report - Request for Sample

Segment Analysis

The global next-generation cancer diagnostic devices market is segmented based on technology, cancer type, application, end-user, and region.

Next-generation Sequencing segment is expected to dominate the global next-generation cancer diagnostic devices market share

The Next-generation Sequencing segment is anticipated to dominate the global next-generation cancer diagnostic devices market owing to the technology's capacity to give thorough genetic profiling, which is critical for understanding cancer biology driving individualized treatment regimens, and increasing the number of cancer cases. NGS allows for the simultaneous study of numerous genes, identifying uncommon mutations, fusion genes, and structural alterations that are crucial for proper cancer diagnosis and treatment selection.

One of the primary technological developments sustaining the NGS segment's growth is the remarkable drop in sequencing costs. Whole genome sequencing costs have dropped from tens of thousands of dollars to roughly $1,000, making it more affordable for therapeutic applications. This cost reduction has been made possible by advances in sequencing technology, such as better reagents and automated platforms that boost throughput while lowering operational costs. Furthermore, advances in bioinformatics tools have improved data analytic skills, enabling more efficient interpretation of complicated genomic data. These enhancements allow healthcare practitioners to provide NGS as a standard diagnostic tool, further consolidating its commercial position.

For instance, in October 2023, Philips has collaborated with Quibim, an imaging biomarker specialist, to create next-generation AI-based imaging and reporting solutions specifically for magnetic resonance (MR) prostate screenings. This collaboration intends to improve prostate cancer detection and treatment by combining Philips' superior MR imaging technology with Quibim's AI-powered QP-Prostate software. The major goal is to automate prostate gland segmentation in magnetic resonance images, which would not only standardize reporting but also give clinicians with key quantitative insights required for accurate diagnosis and individualized treatment programs.

Geographical Analysis

North America is expected to hold a significant position in the global next-generation cancer diagnostic devices market share

North America is anticipated to hold a significant portion of the global next-generation cancer diagnostic devices market owing to the rising prevalence of cancer, technological advancements, recent product launches and approvals, strategic partnerships, and increasing awareness. The higher prevalence of cancer in North America also contributes to the increased demand for advanced diagnostic solutions. Rising awareness of cancer screening and early detection fuels this demand, prompting healthcare practitioners to explore novel solutions such as Next Generation Sequencing (NGS) and other advanced diagnostic technologies. As cancer rates rise, the need for effective diagnostics expands, strengthening North America's position as the dominant market.

For instance, according to an article published by the National Institute of Health, in January 2024, in 2024, 2,001,140 new cancer cases and 611,720 cancer deaths are projected to occur in the United States. Cancer mortality continued to decline through 2021, averting over 4 million deaths since 1991 because of reductions in smoking, earlier detection for some cancers, and improved treatment options in both adjuvant and metastatic settings. However, these gains are threatened by increasing incidence for 6 of the top 10 cancers.

Technological advancements like the incorporation of AI and machine learning into diagnostic processes is yet another key technical achievement. AI systems can quickly and accurately scan massive volumes of genomic data, assisting physicians in identifying actionable mutations that inform individualized therapy options. This collaboration between NGS and AI not only simplifies workflows but also improves patient outcomes by allowing for more accurate therapy methods. For instance, in September 2023, Pillar Biosciences, Inc., the leader in Decision Medicine, announced the global launch of oncoReveal Core LBx, a research-use-only (RUO) next-generation sequencing (NGS) kit designed to enable laboratories with a solution for liquid biopsy-based pan-cancer tumor profiling.

Asia Pacific is growing at the fastest pace in the global next-generation cancer diagnostic devices market

One of the key drivers of this expansion is Asia Pacific's huge and expanding population, which contributes to an increased incidence of oncological disorders. As the population grows, so does the number of people at risk for cancer, resulting in a greater demand for sophisticated diagnostic tools. Countries such as China and India have unusually high rates of cancer incidence as a result of lifestyle changes, urbanization, and aging populations. This demographic transition pushes healthcare systems to prioritize early detection and effective treatment choices, accelerating the deployment of next-generation cancer diagnostic technologies.

For instance, according to the National Institute of Health, the expected number of cancer cases in India for 2022 is 14,61,427 (crude rate: 100.4 per 100,000). In India, one out of every nine people is likely to develop cancer over his or her lifetime. Males and females were most likely to develop lung and breast cancer, respectively. The increasing number of cancer cases increases the demand for cancer testing and the comprehensive genomic profiling of the cancer tumor to analyze the state of the cancer and design the treatment accordingly. So, the increasing number of cancer cases makes this region the fastest growing region.

Competitive Landscape

The major global players in the global next-generation cancer diagnostic devices market include GE HealthCare, Illumina, Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Koninklijke Philips N.V, QIAGEN, Agilent Technologies, Inc., Abbott, Thermo Fisher Scientific Inc., BD among others.

Emerging Players

PathAI, Karius, and OncoOne among others

Key Developments

In May 2024, Foundation Medicine Inc. announced the U.S. launch of FoundationOneRNA, a tissue-based RNA sequencing test for the detection of cancer-related fusions across 318 genes. FoundationOne RNA enables reporting of fusions in all solid tumors and may be valuable for detecting fusions in certain cancers, such as non-small cell lung cancer (NSCLC), pancreatic cancer, cholangiocarcinoma, sarcoma, thyroid cancer, and bladder cancer.

Why Purchase the Report?

Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
Post-market Surveillance: Uses post-market data to enhance product safety and access.
Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global next-generation cancer diagnostic devices market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
Supply Chain: Distribution and Supply Chain Managers.
Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
Academic & Research: Academic Institutions.

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Technology
3.2. Snippet by Cancer Type
3.3. Snippet by Application
3.4. Snippet by End-User
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.2. Increasing Demand for Next-Generation Cancer Diagnostic Devices
- 4.1.3. Restraints
- 4.1.4. High Costs of Advanced Diagnostics Technologies
- 4.1.5. Opportunity
- 4.1.6. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Reimbursement Analysis
5.6. Patent Analysis
5.7. SWOT Analysis
5.8. DMI Opinion

6. By Technology

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 6.1.2. Market Attractiveness Index, By Technology
6.2. Next-generation Sequencing*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. qPCR & Multiplexing
6.4. Lab-on-a-chip (LOAC)
6.5. Protein Microarrays
6.6. DNA Microarrays

7. By Cancer Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 7.1.2. Market Attractiveness Index, By Cancer Type
7.2. Lung Cancer*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Breast Cancer
7.4. Colorectal Cancer
7.5. Cervical Cancer
7.6. Others

8. By Application

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.1.2. Market Attractiveness Index, By Application
8.2. Biomarker Development*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. CTC Analysis
8.4. Proteomic Analysis
8.5. Epigenetic Analysis
8.6. Genetic Analysis

9. By End User

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Cancer Research Institutes
9.4. Diagnostic Centres

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.2.8. The U.S.
- 10.2.9. Canada
- 10.2.10. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), Product Type
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.3.9. Germany
- 10.3.10. UK
- 10.3.11. France
- 10.3.12. Italy
- 10.3.13. Spain
  - 10.3.13.1. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.4.8. Brazil
- 10.4.9. Argentina
- 10.4.10. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.5.8. China
- 10.5.9. India
- 10.5.10. Japan
- 10.5.11. South Korea
- 10.5.12. Rest of Asia-Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. GE HealthCare*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. Illumina, Inc.
12.3. Novartis AG
12.4. F. Hoffmann-La Roche Ltd
12.5. Koninklijke Philips N.V
12.6. QIAGEN
12.7. Agilent Technologies, Inc.
12.8. Abbott
12.9. Thermo Fisher Scientific Inc.
12.10. BD

LIST NOT EXHAUSTIVE